• Recently, Savara announced that the US FDA accepted its biologics license application for MOLBREEVI for autoimmune pulmonary alveolar proteinosis, assigning a PDUFA target action date of November 22, while CFO David Lowrance exercised 580,187 stock options and sold 394,528 shares.
• This regulatory milestone and executive share activity highlight both the advancing path toward a potential first-in-class therapy and how insiders are managing their equity exposure at a key moment for the company.
• With the FDA’s acceptance of MOLBREEVI’s application, we’ll examine how this regulatory progress shapes Savara’s investment narrative and risk profile.

The latest GPUs need a type of rare earth metal called Terbium and there are only 30…